Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -1293.5% | n/a |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 8.1 | n/a |
Pr/Book | n/a |
Latest | F'cast | |
---|---|---|
Revenue | -32.7% | n/a |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
30-Jun-20 | n/a | (10.61) | (16.00)¢ | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-21 | 1.49 | (35.79) | (43.00)¢ | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-22 | 2.97 | (49.63) | (78.00)¢ | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-23 | 3.40 | (45.60) | (55.00)p | n/a | n/a | n/a | n/a | 0.0% |
30-Jun-24 | 2.29 | (33.45) | (31.00)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Audited Full Year Fiscal 2024 Results | 21-Nov-2024 | 07:00 | RNS |
Financial Results for Q1 of Fiscal Year 2025 | 20-Nov-2024 | 07:00 | RNS |
Holding(s) in Company | 08-Nov-2024 | 09:31 | RNS |
Renalytix terminates formal sale process | 20-Aug-2024 | ShareCast |
Renalytix test gets US Medicare coverage determi... | 14-Jun-2024 | ShareCast |
Renalytix surges on takeover approach | 04-Mar-2024 | ShareCast |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 7.75p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 50.40p |
52 Week Low | 7.20p |
Volume | 194,880 |
Shares Issued | 189.93m |
Market Cap | £14.72m |
Beta | 1.48 |
RiskGrade | 348 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:27 | 1,000 @ 7.50p |
15:02 | 66,547 @ 7.50p |
12:37 | 82,146 @ 7.20p |
12:22 | 32 @ 7.50p |
11:41 | 5,727 @ 7.50p |
You are here: research